Getting Antibiotics Right the First Time
Real-time molecular diagnostic interpretation. Precision therapeutic guidance. True antibiotic stewardship.
ATA partners with providers and PCR labs nationwide to deliver highly customized, pharmacist-reviewed therapy guidance based on resistance gene detection and pathogen relevance. We take the guesswork out of prescribing antibiotics so your patients get the right treatment, right away.
We’re Molecular Pharmacists, Not Algorithms
We don’t rely on black-box AI. Every ATAReport™ is reviewed by a clinically trained, PCR-specialized PharmD who evaluates:
Pathogen identification
Resistance gene profiles
Infection site and co-infections
Patient-specific factors like allergies and comorbidities
Each report includes therapy options—not just a list of antibiotics—but customized to each individual patient.
What We Provide
ATAReport™ | Molecular Interpretation Services
- Review of qPCR pathogen + gene data
- Targeted therapy guidance, including oral, IM, and IV options
- ESBL and AmpC workaround strategies
- CMS isolation alerts and epidemiology data
- Patient-specific dosing and special considerations
Plus:
- Monthly CMS-compliant stewardship reports
- Custom antibiotic formularies for PCR labs
- PGX review and analysis
- 24/7 peer-to-peer provider consultations
- Panel consultation and HL7/API integration
ATA vs. the Rest
ATA
Typical Competitor
Approach
Clinical pharmacist review
AI algorithms or static databases
Therapy Style
Patient-specific, targeted
One-size-fits-all
Dosing
Universal standards from IDSA, JAMA, Sanford Guide, John Hopkins, and many medical association guidelines.
Standardized dose
Pathogen View
Multiorganism & multidrug
Single pathogen, single drug
Detection Base
Semi-quantitative + clinical data
Qualitative only
ESBL/AmpC Strategies
Yes
Often not addressed
Peer-to-Peer Access
24/7 live response
Delayed response
Antibiotic Stewardship
True, customized
Often misleading
ATA vs. the Rest
Approach
ATA
Clinical pharmacist review
Typical Competitor
AI algorithms or static databases
Therapy Style
ATA
Patient-specific, targeted
Typical Competitor
One-size-fits-all
Dosing
ATA
Universal standards from IDSA, JAMA, Sanford Guide, John Hopkins, and many medical association guidelines.
Typical Competitor
Standardized dose
Pathogen View
ATA
Multiorganism & multidrug
Typical Competitor
Single pathogen, single drug
Detection Base
ATA
Semi-quantitative + clinical data
Typical Competitor
Qualitative only
ESBL/AmpC Strategies
ATA
Yes
Typical Competitor
Often not addressed
Peer-to-Peer Access
ATA
24/7 live response
Typical Competitor
Delayed response
Antibiotic Stewardship
ATA
True, customized
Typical Competitor
Often performative
Changing Outcomes Requires a Different Approach
✔ Reduces inappropriate prescribing
✔ Shortens recovery time
✔ Decreases hospital admissions
✔ Preserves life-saving antibiotics
ATA offers the most comprehensive molecular PCR analysis and therapy guidance in the country, backed by our patent-pending process and team-based clinical approach.
The Rising Threat of Antimicrobial Resistance
Antibiotic resistance is a global public health crisis. Each year in the U.S. alone:
- 2.8 million drug-resistant infections occur
- 700,000+ people die worldwide due to resistance
- $20 billion is added to our healthcare burden
Up to 50% of antibiotics are still prescribed incorrectly.
We’re committed to changing that.
ATA’s clinical guidance protects the efficacy of life-saving antibiotics like carbapenems, with patent-pending approaches designed to address ESBL and AmpC gene challenges.
Use Our 12-Step Process to Get Antibiotics Right the First Time
If you’re managing complex infections with qPCR results in hand, we can help you get the next step right.